https://www.selleckchem.com/pr....oducts/act001-dmamcl
Most patients ( 80%) required fewer infusions with BAY 94-9027 prophylaxis versus their previous standard-half-life (SHL) rFVIII product. Lower bleeding and joint bleeding rates were observed over time from the prestudy to the extension study period in all treatment regimens. Compared with SHL FVIII, BAY 94-9027 prophylaxis allows patients to reduce infusion frequency with maintained or improved protection from bleeds.Sepsis is a life-threatening complication of infection and is closely associated with coagulation abnormalitie
Beğen
Yorum Yap
Paylaş
